Top 10 AI-Powered Biotech Stocks to Buy Right Now

8. BioNTech SE (NASDAQ:BNTX)

Number of Hedge Fund Holders: 29

BioNTech SE (NASDAQ:BNTX) is among the best biotech stocks. 

TheFly reported on April 10 that Morgan Stanley slightly increased its price target on BNTX from $125 to $126 while maintaining an Overweight rating. The adjustment was part of broader updates across its biopharma coverage, incorporating recent industry data trends from IQVIA and incorporating intra-quarter performance indicators ahead of first-quarter earnings across the sector.

Moreover, on April 12, BioNTech SE (NASDAQ:BNTX) and its partner DualityBio reported positive findings from a Phase 2 cohort evaluating trastuzumab pamirtecan (BNT323/DB-1303), an antibody-drug conjugate targeting HER2-expressing advanced endometrial cancer. The study included patients whose disease had progressed after prior chemotherapy, with or without checkpoint inhibitor therapy, as part of a broader early- and mid-stage clinical program across multiple solid tumors.

Results showed meaningful anti-tumor activity, with confirmed responses observed across different levels of HER2 expression and consistent outcomes regardless of prior immunotherapy exposure. The treatment demonstrated a manageable safety profile. In a key efficacy measure, the cohort met its primary endpoint, showing a confirmed objective response rate of 49.3% in previously checkpoint-treated patients and 47.9% overall, along with a median progression-free survival of 8.1 months. The data were scheduled for presentation at a major oncology meeting.

BioNTech SE (NASDAQ:BNTX) is an AI-driven biotechnology company focused on next-generation immunotherapies, including mRNA, antibody-drug conjugates, and cell therapies for cancer and infectious diseases. It integrates advanced AI and supercomputing across drug discovery, clinical development, and manufacturing to accelerate innovation.